BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 16230180)

  • 1. Efficacy of BTA stat, cytology, and survivin in bladder cancer surveillance over 5 years in patients with spinal cord injury.
    Davies B; Chen JJ; McMurry T; Landsittel D; Lewis N; Brenes G; Getzenberg RH
    Urology; 2005 Oct; 66(4):908-11. PubMed ID: 16230180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dilemma of suspicious urine cytology in patients being followed for bladder cancer.
    Raitanen MP; Aine R; Kylmälä T; Kallio J; Liukkonen T; Tammela T;
    Ann Chir Gynaecol; 2001; 90(4):256-9. PubMed ID: 11820413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer.
    Raitanen MP; Leppilahti M; Tuhkanen K; Forssel T; Nylund P; Tammela T;
    Ann Chir Gynaecol; 2001; 90(4):261-5. PubMed ID: 11820414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparative study of BTA stat test, NMP-22, and cytology in the diagnosis of bladder cancer].
    Gutiérrez Baños JL; Rebollo Rodrigo MH; Antolín Juarez F; Martín García B; Hernández Rodríguez R; Portillo Martín JA; Correas Gómez MA; del Valle Schaan JI; Roca Edreira A; de Diego Rodríguez E; Radó Velázquez MA
    Arch Esp Urol; 2000; 53(1):21-7. PubMed ID: 10730421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The BTA stat test in the follow-up for bladder cancer].
    Gutiérrez Baños JL; Martín García B; de Diego Rodríguez E; Hernández Rodríguez R; Portillo Martín JA; Correas Gómez MA; del Valle Schaan JI; Roca Edreira A; Rado Velázquez MA
    Arch Esp Urol; 1999 Oct; 52(8):856-61. PubMed ID: 10589117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Usefulness of BTA Stat test (Bard) in the diagnosis of bladder cancer. Preliminary results and comparison with cytology and cystoscopy].
    Gutiérrez Baños JL; Martín García B; Hernández Rodríguez R; Portillo Martín JA; Correas Gómez MA; del Valle Schaan JI; Roca Edreira A; Villanueva Peña A; Gutíerrez García R; De Diego Rodríguez E; Rado Velázquez MA
    Arch Esp Urol; 1998 Oct; 51(8):778-82. PubMed ID: 9859583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A side by side comparison of cytology and biomarkers for bladder cancer detection.
    Schroeder GL; Lorenzo-Gomez MF; Hautmann SH; Friedrich MG; Ekici S; Huland H; Lokeshwar V
    J Urol; 2004 Sep; 172(3):1123-6. PubMed ID: 15311054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence.
    Boman H; Hedelin H; Holmäng S
    J Urol; 2002 Jan; 167(1):80-3. PubMed ID: 11743280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma.
    Babjuk M; Soukup V; Pesl M; Kostírová M; Drncová E; Smolová H; Szakacsová M; Getzenberg R; Pavlík I; Dvorácek J
    Urology; 2008 Apr; 71(4):718-22. PubMed ID: 18387400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninvasive detection of bladder cancer with the BTA stat test.
    Pode D; Shapiro A; Wald M; Nativ O; Laufer M; Kaver I
    J Urol; 1999 Feb; 161(2):443-6. PubMed ID: 9915422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine.
    Halling KC; King W; Sokolova IA; Karnes RJ; Meyer RG; Powell EL; Sebo TJ; Cheville JC; Clayton AC; Krajnik KL; Ebert TA; Nelson RE; Burkhardt HM; Ramakumar S; Stewart CS; Pankratz VS; Lieber MM; Blute ML; Zincke H; Seelig SA; Jenkins RB; O'Kane DJ
    J Urol; 2002 May; 167(5):2001-6. PubMed ID: 11956427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of the prostate limits the usefulness of survivin for the detection of bladder cancer.
    Davies B; Chen J; Modugno F; Weissfeld J; Landsittel D; Dhir R; Nelson J; Getzenberg RH
    J Urol; 2005 Nov; 174(5):1767-70. PubMed ID: 16217280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic evaluation of apoptosis inhibitory gene and tissue inhibitor matrix metalloproteinase-2 in patients with bladder cancer.
    Eissa S; Shabayek MI; Ismail MF; El-Allawy RM; Hamdy MA
    IUBMB Life; 2010 May; 62(5):394-9. PubMed ID: 20408180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Quantification of bladder tumor antigen (BTA trak) and its correlation with bladder cancer grade and stage].
    Rodríguez Martínez JJ; Escaf Barmadah S; Allende MT; Raigoso P; Martín Benito JL; Pérez García FJ; Fernández Gómez JM
    Arch Esp Urol; 2000; 53(1):1-6. PubMed ID: 10730418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A; Kumar R; Gupta NP
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear matrix protein 22 as adjunct to urine cytology and cystoscopy in follow-up of superficial TCC of urinary bladder.
    Gupta NP; Sharma N; Kumar R
    Urology; 2009 Mar; 73(3):592-6; discussion 596-7. PubMed ID: 19168205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of urine cytology for diagnosing bladder cancer in spinal cord injured patients.
    Stonehill WH; Goldman HB; Dmochowski RR
    J Urol; 1997 Jun; 157(6):2112-4. PubMed ID: 9146593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bladder cancer in patients with spinal cord injuries.
    Subramonian K; Cartwright RA; Harnden P; Harrison SC
    BJU Int; 2004 Apr; 93(6):739-43. PubMed ID: 15049983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bladder tumor antigen stat test in non-urothelial malignant urologic conditions.
    Wald M; Halachmi S; Amiel G; Madjar S; Mullerad M; Miselevitz I; Moskovitz B; Nativ O
    Isr Med Assoc J; 2002 Mar; 4(3):174-5. PubMed ID: 11908255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of urinary biomarkers for bladder cancer surveillance: patient perspectives.
    Yossepowitch O; Herr HW; Donat SM
    J Urol; 2007 Apr; 177(4):1277-82; discussion 1282. PubMed ID: 17382711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.